Predicting substrate selectivity between UGT1A9 and UGT1A10 using molecular modelling and molecular dynamics approach

Molecular Simulation

Volumn 42, Issue 4, 2016, Pages 270-288

  Tripathi, Satya Prakash ^a   Prajapati, Rameshwar ^a   Verma, Neha ^a   Sangamwar, Abhay T ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

docking; glucuronidation; molecular dynamics; molecular modelling; UGT

Indexed keywords

COMPUTER AIDED SOFTWARE ENGINEERING; DOCKING; GLUCOSE; MOLECULAR DYNAMICS; MOLECULAR MODELING;

C-TERMINAL DOMAINS; GLUCURONIDATION; HOMOLOGY MODELLING; MOLECULAR DYNAMICS SIMULATIONS; MULTIPLE SEQUENCE ALIGNMENTS; N-TERMINAL DOMAINS; SUBSTRATE BINDING; SUBSTRATE SELECTIVITY;

SUBSTRATES;

EID: 84943353279     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927022.2015.1044451     Document Type: Article

References (73)

1. Remmel R, Nagar S, Argikar U. Conjugative metabolism of drugs. In: Donglu Z, Mingshe Z, Griffith WH., editors. Drug metabolism in drug design and development. New Jersey: Wiley; 2007. p. 37-88.
2. Xu C, Li CY-T, Kong A-NT. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005; 28: 249-268. doi: 10.1007/BF02977789.
3. ∗. Drug Metab Rev. 1999; 31: 817-899. doi: 10.1081/DMR-100101944.
4. Burchell B. Transformation reactions: glucuronidation. Handbook of drug metabolism. New York (NY): Marcel Dekker, Inc.; 1999. p. 153-173.
5. Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, Strassburg CP. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006; 44: 1324-1332. doi: 10.1002/hep.21361.
6. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Gigleux SF, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Roy Chowdhury J, Ritter J, Tephly TR, Schachter H, Tephly T, Tipton K, Nebert DW. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics. 1997; 7: 255-269. doi: 10.1097/00008571-199708000-00001.
7. Tripathi SP, Bhadauriya A, Patil A, Sangamwar AT. Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights. Drug Metab Rev. 2013; 45: 231-252. doi: 10.3109/03602532.2013.767345.
8. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos. 2008; 36: 1461-1464. doi: 10.1124/dmd.108.021428.
9. Ohno S, Nakajin S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos. 2009; 37: 32-40. doi: 10.1124/dmd.108.023598.
10. Nishimura M, Koeda A, Morikawa H, Satoh T, Narimatsu S, Naito S. Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab Pharmacokinet. 2009; 24: 139-144. doi: 10.2133/dmpk.24.139.
11. Strassburg CP, Manns MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon: identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem. 1998; 273: 8719-8726. doi: 10.1074/jbc.273.15.8719.
12. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther. 1991; 51: 347-369. doi: 10.1016/0163-7258(91)90065-T.
13. Alonen A, Aitio O, Hakala K, Luukkanen L, Finel M, Kostiainen R. Biosynthesis of dobutamine monoglucuronides and glucuronidation of dobutamine by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005; 33: 657-663. doi: 10.1124/dmd.104.002139.
14. Sten T, Qvisen S, Uutela Pi, Luukkanen L, Kostiainen R, Finel M. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab Dispos. 2006; 34: 1488-1494. doi: 10.1124/dmd.106.010371.
15. 2-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos. 2008; 36: 2307-2315.
16. Itäaho K, Uutela PI, Kostiainen R, Radominska-Pandya A, Finel M. Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos. 2009; 37: 768-775.
17. Ciotti M, Cho JW, George J, Owens IS. Required buried α-helical structure in the bilirubin UDP-glucuronosyltransferase, UGT1A1, contains a nonreplaceable phenylalanine. Biochemistry. 1998; 37: 11018-11025. doi: 10.1021/bi980747q.
18. Senay C, Battaglia E, Chen G, Breton R, Fournel-Gigleux S, Magdalou J, Radominska-Pandya A. Photoaffinity labeling of the aglycon binding site of the recombinant human liver UDP-glucuronosyltransferase UGT1A6 with 7-azido-4-methylcoumarin. Arch Biochem Biophys. 1999; 368: 75-84. doi: 10.1006/abbi.1999.1300.
19. Xiong Y, Bernardi D, Bratton S, Ward MD, Battaglia E, Finel M, Drake RR, Radominska-Pandya A. Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis. Biochemistry. 2006; 45: 2322-2332. doi: 10.1021/bi0519001.
20. Fujiwara R, Nakajima M, Yamamoto T, Nagao H, Yokoi T. In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. Drug Metab Pharmacokinet. 2009; 24: 235-244. doi: 10.2133/dmpk.24.235.
21. Itäaho K, Laakkonen L, Finel M. How many and which amino acids are responsible for the large activity differences between the highly homologous UDP-glucuronosyltransferases (UGT) 1A9 and UGT1A10? Drug Metab Dispos. 2009; 38: 687-696.
22. Dong D, Wu B. In silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the volsurf approach. J Pharm Sci. 2012; 101: 3531-3539. doi: 10.1002/jps.23100.
23. Bolam DN, Roberts S, Proctor MR, Turkenburg JP, Dodson EJ, Martinez-Fleites C, Yang M, Davis BG, Davies GJ, Gilbert HJ. The crystal structure of two macrolide glycosyltransferases provides a blueprint for host cell antibiotic immunity. Proc Natl Acad Sci. 2007; 104: 5336-5341. doi: 10.1073/pnas.0607897104.
24. Shao H, He X, Achnine L, Blount JW, Dixon RA, Wang X. Crystal structures of a multifunctional triterpene/flavonoid glycosyltransferase from Medicago truncatula. Plant Cell Online. 2005; 17: 3141-3154. doi: 10.1105/tpc.105.035055.
25. Mittler M, Bechthold A, Schulz GE. Structure and action of the C-C bond-forming glycosyltransferase UrdGT2 involved in the biosynthesis of the antibiotic urdamycin. J Mol Biol. 2007; 372: 67-76. doi: 10.1016/j.jmb.2007.06.005.
26. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo MR. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol. 2007; 369: 498-511. doi: 10.1016/j.jmb.2007.03.066.
27. Larkin MAM, Blackshields GG, Brown NPN, Chenna RR, McGettigan PAP, McWilliam HH, Valentin FF, Wallace IMI, Wilm AA, Lopez RR, Thompson JDJ, Gibson TJT, Higgins DGD. Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23: 2947-2948. doi: 10.1093/bioinformatics/btm404.
28. Šali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. Evaluation of comparative protein modeling by MODELLER. Proteins: Struct., Funct., Bioinf. 1995; 23: 318-326. doi: 10.1002/prot.340230306.
29. MacKerell ADAD, Bashford DD, Bellott MM, Dunbrack RLRL, Evanseck JDJD, Field MJMJ, Fischer SS, Gao JJ, Guo HH, Ha SS, Joseph-McCarthy DD, Kuchnir LL, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 1998; 102: 3586-3616. doi: 10.1021/jp973084f.
30. Pandey A, Tripathi S, Gopi Mohan C. Harnessing human n-type Ca 2+ channel receptor by identifying the atomic hotspot regions for its structure-based blocker design. Mol Inform. 2012; 31: 643-657. doi: 10.1002/minf.201200025.
31. SYBYL Molecular Modeling System v. St. Louis (MO): Tripos, Inc. 63144, USA.
32. Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996; 17: 490-519. 10.1002/(SICI)1096-987X(199604)17:5/6<490:AID-JCC1>3.0.CO;2-P.
33. Powell MJD. Numerical analysis: and lecture notes in mathematics. In: A fast algorithm for nonlinearly constrained optimization calculations. Berlin, Heidelberg: Springer; 2006. p. 144-157.
34. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B. 2001; 105: 6474-6487. doi: 10.1021/jp003919d.
35. Vijayan RSK, Trivedi N, Roy SN, Bera I, Manoharan P, Payghan PV, Bhattacharyya D, Ghoshal N. Modeling the closed and open state conformations of the GABA a ion channel-plausible structural insights for channel gating. J Chem Inf Model. 2012; 52: 2958-2969. doi: 10.1021/ci300189a.
36. Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, Guillemette C. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab. 2004; 89: 5222-5232. doi: 10.1210/jc.2004-0331.
37. Pritchett LE, Atherton KM, Mutch E, Ford D. Glucuronidation of the soyabean isoflavones genistein and daidzein by human liver is related to levels of UGT1A1 and UGT1A9 activity and alters isoflavone response in the MCF-7 human breast cancer cell line. J Clin Biochem Nutr. 2008; 19: 739-745. doi: 10.1016/j.jnutbio.2007.10.002.
38. Tang L, Singh R, Liu Z, Hu M. Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Mol Pharma. 2009; 6: 1466-1482. doi: 10.1021/mp8002557.
39. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol. 2002; 62: 608-617.
40. Oguri T, Takahashi T, Miyazaki M, Isobe T, Kohno N, Mackenzie PI, Fujiwara Y. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res. 2004; 24: 2893-2896.
41. Zhang L, Lin G, Zuo Z. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharm Res. 2006; 24: 81-89. doi: 10.1007/s11095-006-9126-y.
42. Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos. 2002; 30: 694-700. doi: 10.1124/dmd.30.6.694.
43. Mizuma T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm. 2009; 378: 140-141. doi: 10.1016/j.ijpharm.2009.05.044.
44. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005; 33: 1027-1035. doi: 10.1124/dmd.104.002527.
45. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, Wieland E. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol. 2001; 132: 1027-1034. doi: 10.1038/sj.bjp.0703898.
46. Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 2003; 307: 117-128. doi: 10.1124/jpet.103.054072.
47. Ramírez J, Iyer L, Journault K, Bélanger P, Innocenti F, Ratain MJ, Guillemette C. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res. 2002; 19: 588-594.
48. Offen W, Martinez-Fleites C, Yang M, Kiat-Lim E, Davis BG, Tarling CA, Ford CM, Bowles DJ, Davies GJ. Structure of a flavonoid glucosyltransferase reveals the basis for plant natural product modification. EMBO J. 2006; 25: 1396-1405. doi: 10.1038/sj.emboj.7600970.
49. Patana A-S, Kurkela M, Goldman A, Finel M. The human UDP-glucuronosyltransferase: identification of key residues within the nucleotide-sugar binding site. Mol Pharmacol. 2007; 72: 604-611. doi: 10.1124/mol.107.036871.
50. Patana A-S, Kurkela M, Finel M, Goldman A. Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases. Protein Eng Des Sel. 2008; 21: 537-543. doi: 10.1093/protein/gzn030.
51. Case DA, Darden TA, Cheatham TEIII, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM. AMBER 11. San Francisco (CA): University of California; 2010.
52. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc. 1995; 117: 5179-5197. doi: 10.1021/ja00124a002.
53. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004; 25: 1157-1174. doi: 10.1002/jcc.20035.
54. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983; 79: 926-935. doi: 10.1063/1.445869.
55. Van Gunsteren WF, Berendsen HJC. Algorithms for macromolecular dynamics and constraint dynamics. Mol Phys. 1977; 34: 1311-1327. doi: 10.1080/00268977700102571.
56. Darden T, York D, Pedersen L. Particle mesh Ewald: an Nslog(N) method for Ewald sums in large systems. J Chem Phys. 1993; 98: 10089-10092. doi: 10.1063/1.464397.
57. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14: 33-38. doi: 10.1016/0263-7855(96)00018-5.
58. Laakkonen L, Finel M. A molecular model of the human UDP-glucuronosyltransferase 1A1, its membrane orientation, and the interactions between different parts of the enzyme. Mol Pharmacol. 2010; 77: 931-939. doi: 10.1124/mol.109.063289.
59. Locuson CW, Tracy TS. Comparative modelling of the human UDP-glucuronosyltransferases: insights into structure and mechanism. Xenobiotica. 2007; 37: 155-168. doi: 10.1080/00498250601129109.
60. ∗ 6. Mol Pharmacol. 1997; 51: 406-413.
61. Radominska-Pandya A, Bratton SM, Redinbo MR, Miley MJ. The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families. Drug Metab Rev. 2010; 42: 133-144. doi: 10.3109/03602530903209049.
62. Lewis BC, Mackenzie PI, Elliot DJ, Burchell B, Bhasker CR, Miners JO. Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem. Pharmacol. 2007; 73 (9): 1463-1473. doi: 10.1016/j.bcp.2006.12.021.
63. Chou K-C. Structural bioinformatics and its impact to biomedical science. Curr Med Chem. 2004; 11: 2105-2134. doi: 10.2174/0929867043364667.
64. Wei D-Q, Du Q-S, Sun H, Chou K-C. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem Bioph Res Co. 2006; 344: 1048-1055. doi: 10.1016/j.bbrc.2006.03.210.
65. Lewis DFV. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol. 2000; 60: 293-306. doi: 10.1016/S0006-2952(00)00335-X.
66. Chou K-C, Wei D-Q, Zhong W-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun. 2003; 308: 148-151. doi: 10.1016/S0006-291X(03)01342-1.
67. Wang J-F, Chou K-C. Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem Biophys Res Commun. 2009; 390: 608-612. doi: 10.1016/j.bbrc.2009.10.014.
68. Chou K-C. Low-frequency collective motion in biomacromolecules and its biological functions. Biophys Chem. 1988; 30: 3-48. doi: 10.1016/0301-4622(88)85002-6.
69. Chou K-C, Tomasselli AG, Heinrikson RL. Prediction of the tertiary structure of a caspase-9/inhibitor complex. FEBS Lett. 2000; 470: 249-256. doi: 10.1016/S0014-5793(00)01333-8.
70. Wang S-Q, Du Q-S, Huang R-B, Zhang D-W, Chou K-C. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochem Biophys Res Commun. 2009; 386: 432-436. doi: 10.1016/j.bbrc.2009.06.016.
71. Wu B, Morrow JK, Singh R, Zhang S, Hu M. Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J Pharmacol Exp Ther. 2011; 336: 403-413. doi: 10.1124/jpet.110.175356.
72. Brazier-Hicks M, Offen WA, Gershater MC, Revett TJ, Lim E-K, Bowles DJ, Davies GJ, Edwards R. Characterization and engineering of the bifunctional N- and O-glucosyltransferase involved in xenobiotic metabolism in plants. Proc Natl Acad Sci. 2007; 104: 20238-20243. doi: 10.1073/pnas.0706421104.
73. Mulichak AM, Losey HC, Walsh CT, Garavito RM. Structure of the UDP-glucosyltransferase GtfB that modifies the heptapeptide aglycone in the biosynthesis of vancomycin group antibiotics. Structure. 2001; 9: 547-557. doi: 10.1016/S0969-2126(01)00616-5.